Evolus Gets Second Chance in Botox Battle With Abbvie’s Allergan

Evolus Inc. got a second chance to persuade a U.S. trade agency to let it continue importing Jeuveau, a rival to the Botox wrinkle treatment made by AbbVie Inc.’s Allergan.

The U.S. International Trade Commission said it will review a judge’s findings that Jeuveau is made with a secret process stolen from Allergan’s Korean partner, Medytox Inc. A final decision in the case is expected in November. Trade Judge David Shaw has recommended a 10-year ban on Jeuveau imports.

Evolus was up 3.5% to $3.64 at 9:49 a.m. in New York trading after jumping as much as 6.8% ...